Question

请帮助翻译下医学文献 感谢！！

Source
Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. t.vogl@em.uni-frankfurt.de
Abstract
PURPOSE:
To prospectively evaluate the safety and efficacy of microwave ablation therapy of unresectable pulmonary metastases.
MATERIALS AND METHODS:
All patients provided informed consent for this prospective institutional review board-approved study. Eighty patients (30 men, 50 women; mean age, 59.7 years ± 6.4; range, 48-68 years) underwent computed tomography-guided percutaneous microwave ablation of pulmonary metastatic lesions in 130 sessions. The tumors represented metastases from colorectal carcinoma, breast carcinoma, hepatocellular carcinoma, renal cell carcinoma, and bronchogenic carcinoma; there was no evidence of extrapulmonary metastasis for any tumor. Logistic regression analysis was used for evaluation of the statistical significance of factors affecting the end result of microwave ablation therapy. The Kaplan-Meier method was used for estimation of survival rates.
RESULTS:
Complete, successful ablation was achieved in 95 (73.1%) of 130 lesions. Successful tumor ablation was significantly more frequent for lesions with a maximal axial diameter of 3 cm or smaller (90 of 110) than for lesions greater than 3 cm in maximal axial diameter (five of 20) (P < .0001) and for peripheral lesions (80 [80%] of 100) than for centrally located lesions (15 [50%] of 30) (P = .002). The histopathologic type of the metastasis did not significantly correlate with the ablation result (P > .3). The 12- and 24-month survival rates were 91.3% and 75%, respectively. There was no intraprocedural death, and the overall 60-day mortality rate after ablation was 0%. Higher survival rates were observed in patients with tumor-free states after successful ablation than in patients with failed ablation (P = .001). The incidence of pneumothorax was 8.5% (11 of 130). An intercostal chest tube was applied in one (0.8%) of the 11 sessions. Pulmonary hemorrhage developed in eight (6.2%) of 130 sessions.
CONCLUSION:
Microwave ablation therapy may be safely and effectively used as a therapeutic tool for treatment of pulmonary metastases. The efficacy of the treatment is primarily determined by preablation tumor size and location in relation to the hilum.

Answer 1

来源
诊断和放射干预协会，法兰克福医学院，约翰沃尔夫冈歌德大学，奥多-斯德恩-凯，60590法兰克福，德国.t.vogl@em.uni-frankfurt.de
摘要
目的：
评估激光消融治疗肺转移瘤的安全和功效。

材料和方法：
向所有病人提供此研究的知情同意书。80个经受了计算机断层扫描经皮微波消融肺转移瘤治疗130期的病人（30男，50女；平均年龄59.7正负6.5；48-68岁）。肿瘤由直肠癌，乳腺癌，肝癌，肾癌，支气管癌转移形成；没有任何肺外转移肿瘤的迹象。逻辑回归分析被用来评价微波消融疗法统计显著性的影响因素。卡普兰米尔法也被用来估计生存几率。
结果：
完全的、成功的消融成功了95例（73.1%）。成功的肿瘤消融大多出现在直径小于等于3cm的肿瘤（90/110）和周围性损伤（80/100）的病例中，而在大于3CM直径的肿瘤（5/20,P<0.001）和中心性肿瘤(15/30)的病例中，成功率较低(P>0.3)。这种转移瘤组织病理学类型的消融结果没有找出一一对应的关系(P>0.3).12-24个月的存活率分别是91.3%和75%，没有成程序中死亡的个例，全60天死亡率在消融后是0%。观察到比起失败的病人,，成功消融的病人有更高的存活率并没有肿瘤再生迹象（P=0.001）。气胸发生率是8.5%（11/130）.肋间胸导管应用率0.8%（1/11）。肺出血发生率6.2%（8/130）。
总结：
微波消融疗法或许是安全有效的治疗肺转移瘤的工具。治疗功效取决于肿瘤大小和相对于肺门的位置。